MGMT and cancer: The ever evolving face of intra-tumoral heterogeneity has continued the quest for circulating biomarkers for cancer prognosis, however recent reports have supplement to potential consideration list the DNA biomarkers like BRAF, PIK3CA, MGMT, KRAS, TP53, circulating tumor DNA and RNA biomarkers like miR-155, miR21-5p, miR125b-5p, miR200, miR210 and miR221 (Rapisuwon, Vietsch & Wellstein, 2016).